The Mode of Action of Migraine Triggers: A Hypothesis

被引:71
作者
Lambert, Geoffrey A. [1 ]
Zagami, Alessandro S.
机构
[1] Prince Wales Hosp, Inst Neurol Sci, Sch Clin, Randwick, NSW 2031, Australia
来源
HEADACHE | 2009年 / 49卷 / 02期
关键词
migraine; migraine trigger; cerebral cortex; brainstem; trigeminovascular sensory system; CORTICAL SPREADING DEPRESSION; NUCLEUS RAPHE MAGNUS; SPINAL TRIGEMINAL NUCLEUS; MEDULLARY DORSAL-HORN; PRIMARY VISUAL-CORTEX; PHASEOLUS-VULGARIS-LEUKOAGGLUTININ; TRANSCRANIAL MAGNETIC STIMULATION; FAMILIAL HEMIPLEGIC MIGRAINE; MIDBRAIN PERIAQUEDUCTAL GRAY; SUPERIOR SAGITTAL SINUS;
D O I
10.1111/j.1526-4610.2008.01230.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To review conjectured modes of action of migraine triggers and to present a new hypothesis about them. Migraine attacks are initiated in many migraineurs by a variety of "triggers," although in some patients no external trigger can be identified. Many triggers provoke attacks with such a short latency that only some kind of neural mechanism can explain the triggering. We present here a hypothesis that the pain of migraine has its ultimate origin in the cortex, but that the immediate generator is in the brainstem. Our hypothesis is that most migraines have triggers that produce excitation of cortical neurons and that this directly causes withdrawal of descending sensory inhibition originating in the brainstem. A wide range of evidence from the literature that cortical activation induced by a number of different mechanisms often produces headache is presented to support this notion. Several nuclei in the brainstem appear to participate in the selective control of trigeminovascular sensation through descending inhibitory mechanisms that arise in the cortex. In this review we focus on 2 of them, the periaqueductal gray matter and nucleus raphe magnus. Our own past results and those of others show that this inhibition is specific for craniovascular sensation and involves the neurotransmitter 5-hydroxytryptamine. Finally, we summarize our own recent experiments, which show that cortical activation by migraine triggers (including cortical spreading depression) inhibits neuronal discharge in the brainstem and facilitates trigeminovascular sensation. If the hypothesis can be proven and the neurotransmitters involved in the hypothetical trigger pathway can be identified, it may be possible to develop novel migraine preventative therapies.
引用
收藏
页码:253 / 275
页数:23
相关论文
共 244 条
[91]   LOCALIZATION OF H-3 DIHYDROERGOTAMINE BINDING-SITES IN THE CAT CENTRAL-NERVOUS-SYSTEM - RELEVANCE TO MIGRAINE [J].
GOADSBY, PJ ;
GUNDLACH, AL .
ANNALS OF NEUROLOGY, 1991, 29 (01) :91-94
[92]  
Goadsby PJ, 1999, NEUROLOGY, V52, P1522
[93]   Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine [J].
Goadsby, PJ .
CEPHALALGIA, 2002, 22 (02) :107-111
[94]   THE MECHANISM OF CEREBROVASCULAR VASOCONSTRICTION IN RESPONSE TO LOCUS COERULEUS STIMULATION [J].
GOADSBY, PJ ;
LAMBERT, GA ;
LANCE, JW .
BRAIN RESEARCH, 1985, 326 (02) :213-217
[95]   Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT1B/1D receptor:: A central action in migraine? [J].
Goadsby, PJ ;
Hoskin, KL .
ANNALS OF NEUROLOGY, 1998, 43 (06) :711-718
[96]   DIFFERENTIAL-EFFECTS ON THE INTERNAL AND EXTERNAL CAROTID CIRCULATION OF THE MONKEY EVOKED BY LOCUS COERULEUS STIMULATION [J].
GOADSBY, PJ ;
LAMBERT, GA ;
LANCE, JW .
BRAIN RESEARCH, 1982, 249 (02) :247-254
[97]  
GOADSBY PJ, 2006, 11 WORLD C PAIN SYDN, P635
[98]   Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine:: a randomised controlled trial [J].
Goldstein, DJ ;
Roon, KI ;
Offen, WW ;
Ramadan, NM ;
Phebus, LA ;
Johnson, KW ;
Schaus, JM ;
Ferrari, MD .
LANCET, 2001, 358 (9289) :1230-1234
[99]  
GRAHAM JR, 1937, P ASS NERV MENT DIS, P638
[100]   Potential role of female sex hormones in the pathophysiology of migraine [J].
Gupta, Saurabh ;
Mehrotra, Suneet ;
Villalon, Carlos M. ;
Perusquia, Mercedes ;
Saxena, Pramod R. ;
VanDenBrink, Antoinette Maassen .
PHARMACOLOGY & THERAPEUTICS, 2007, 113 (02) :321-340